METASTATIC BREAST CANCER

After receiving chemotherapy either before or after your cancer has spread and if HR-positive, after receiving hormonal therapy LYNPARZA is used as an active treatment to help shrink or slow the growth of inherited BRCA-mutated HER2-negative metastatic breast cancer.

LYNPARZA may help treat your unique type of breast cancer

Breast cancer is a disease that occurs in different cells in the breast. It is said to have metastasized when it has spread through blood vessels and lymph vessels to other parts of the body.

LYNPARZA is an active treatment that gives certain patients the option of treating their specific kind of metastatic breast cancer. LYNPARZA is taken by mouth, so there's no need to go to an infusion center.

BRCA mutations and LYNPARZA

BRCA mutations and LYNPARZA

Your BRCA status plays an important role in your treatment with LYNPARZA. If you have an inherited BRCA mutation, LYNPARZA may be right for you. Talk to your doctor about getting a genetic test to see if you have an inherited BRCA mutation. The sooner you do this after diagnosis, the better informed you and your doctor will be to help determine your treatment plan.

LEARN ABOUT GENETIC TESTING

LYNPARZA is prescribed for two groups of people with

HER2*-negative metastatic breast cancer and an inherited BRCA mutation.

HR†-positive metastatic breast cancer after chemotherapy and hormonal therapy

Triple-negative metastatic breast cancer after chemotherapy

LYNPARZA was tested against chemotherapy in a metastatic breast cancer clinical study, which included these 2 groups of patients. Results from this clinical study are shown below.


*HER2: human epidermal growth factor receptor 2; †HR: hormone receptor.

LYNPARZA could give you MORE TIME progression free

Talk to your doctor about LYNPARZA

Talk to your doctor early about LYNPARZA for this type of metastatic breast cancer.

CLINICAL STUDY RESULTS

Metastatic breast cancer

The OlympiAD study tested 302 people with an inherited BRCA mutation and HER2-negative metastatic breast cancer that was previously treated with chemotherapy, and if HR-positive, treated with hormonal therapy (205 people took LYNPARZA and 97 took chemotherapy).

LYNPARZA delayed disease progression by 7 months LYNPARZA was shown to delay disease progression by a median of 7 months compared with 4.2 months for patients who were given certain chemotherapies.

LYNPARZA lowered the risk of disease progression or death by 42%

People treated with LYNPARZA were 42% less likely to have their cancer grow or spread than those on chemotherapy.

2x the percentage of people saw their tumors shrink than those taking certain chemotherapies

LYNPARZA
52% of people with measurable disease taking LYNPARZA saw their tumors shrink

87 out of 167 people

CERTAIN CHEMOTHERAPIES
23% of people with measurable disease taking certain chemotherapies saw their tumors shrink

15 out of 66 people

52% of people taking LYNPARZA saw their tumors shrink compared to 23% of those taking certain chemotherapies.

These data are based on patients with tumors that responded to LYNPARZA (167 patients) or chemotherapy (66 patients).

LYNPARZA patient information

LYNPARZA patient information

The Breast Cancer Patient Brochure gives you more information on starting and continuing treatment with LYNPARZA.

DOWNLOAD BROCHURE

Downloadable resources

LYNPARZA patient information

Get more information on starting and continuing treatment with LYNPARZA.

DOWNLOAD Breast Cancer Patient Brochure

Tips for managing your treatment

Learn more about the potential side effects of LYNPARZA and how you should work with your doctor to manage them.

DOWNLOAD Tips for Managing Your Treatment Brochure

LYNPARZA caregivers

Our Caregiver Brochure provides useful tips and information. Learn more about the importance of looking after yourself as a caregiver.

DOWNLOAD LYNPARZA Caregiver Brochure

WHAT IS LYNPARZA?

LYNPARZA is a prescription medicine used to treat adults who have:

  • a certain type of abnormal inherited BRCA gene, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to other parts of the body (metastatic). You should have received chemotherapy medicines, either before or after your cancer has spread. If you have hormone receptor (HR)-positive disease, you should have been treated with hormonal therapy. Your healthcare provider will perform a test to make sure that LYNPARZA is right for you

It is not known if LYNPARZA is safe and effective in children.

IMPORTANT SAFETY INFORMATION 

LYNPARZA may cause serious side effects, including: Bone marrow problems called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). Some people who have ovarian cancer or breast cancer and who have received previous treatment with chemotherapy, radiotherapy, or certain other medicines for their cancer have developed MDS or AML during treatment with LYNPARZA. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with LYNPARZA.

Symptoms of low blood cell counts are common during treatment with LYNPARZA, but can be a sign of serious bone marrow problems, including MDS or AML. Symptoms may include weakness, weight loss, fever, frequent infections, blood in urine or stool, shortness of breath, feeling very tired, bruising or bleeding more easily.

    Your healthcare provider will do blood tests to check your blood cell counts:
  • before treatment with LYNPARZA
  • every month during treatment with LYNPARZA
  • weekly if you have low blood cell counts that last a long time. Your healthcare provider may stop treatment with LYNPARZA until your blood cell counts improve

Lung problems (pneumonitis). Tell your healthcare provider if you have any new or worsening symptoms of lung problems, including shortness of breath, fever, cough, or wheezing. Your healthcare provider may do a chest x-ray if you have any of these symptoms. Your healthcare provider may temporarily or completely stop treatment if you develop pneumonitis. Pneumonitis may lead to death.

    Before taking LYNPARZA, tell your healthcare provider about all of your medical conditions, including if you:
  • have lung or breathing problems
  • have kidney problems
  • are pregnant, become pregnant, or plan to who are become pregnant. LYNPARZA can harm your unborn baby and may cause loss of pregnancy (miscarriage)
    • If you are able to become pregnant, your healthcare provider may do a pregnancy test before you start treatment with LYNPARZA
    • Females who are able to become pregnant should use effective birth control (contraception) during treatment with LYNPARZA and for 6 months after the last dose of LYNPARZA. Talk to your healthcare provider about birth control methods that may be right for you. Tell your healthcare provider right away if you become pregnant or think you might be pregnant following treatment with LYNPARZA
    • Males with female partners who are pregnant or able to become pregnant should use effective birth control (contraception) during treatment with LYNPARZA and for 3 months after the last dose of LYNPARZA
    • Do not donate sperm during treatment with LYNPARZA and for 3 months after your final dose
  • are breastfeeding or plan to breastfeed. It is not known if LYNPARZA passes into your breast milk. Do not breastfeed during treatment with LYNPARZA and for 1 month after receiving the last dose of LYNPARZA. Talk to your healthcare provider about the best way to feed your baby during this time

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking LYNPARZA and certain other medicines may affect how LYNPARZA works and may cause side effects.

    How should I take LYNPARZA?
  • Take LYNPARZA tablets exactly as your healthcare provider tells you
  • Do not change your dose or stop taking LYNPARZA unless your healthcare provider tells you to. Your healthcare provider may temporarily stop treatment with LYNPARZA or change your dose of LYNPARZA if you experience side effects
  • Your healthcare provider will decide how long you stay on treatment
  • Do not take more than 4 LYNPARZA tablets in 1 day. If you have any questions about LYNPARZA, talk to your healthcare provider or pharmacist
  • Take LYNPARZA by mouth 2 times a day
  • Each dose should be taken about 12 hours apart
  • Swallow LYNPARZA tablets whole. Do not chew, crush, dissolve, or divide the tablets
  • Take LYNPARZA with or without food
  • If you miss a dose of LYNPARZA, take your next dose at your usual scheduled time. Do not take an extra dose to make up for a missed dose
  • If you take too much LYNPARZA, call your healthcare provider or go to the nearest hospital emergency room right away

What should I avoid while taking LYNPARZA?Avoid grapefruit, grapefruit juice, Seville oranges, and Seville orange juice during treatment with LYNPARZA since they may increase the level of LYNPARZA in your blood.

    LYNPARZA may cause serious side effects (see above). The most common side effects of LYNPARZA are:
  • nausea or vomiting. Tell your healthcare provider if you get nausea or vomiting. Your healthcare provider may prescribe medicines to treat these symptoms
  • low number of red or white blood cells
  • stomach-area (abdominal) pain
  • dizziness
  • tiredness or weakness
  • sore throat or runny nose
  • diarrhea
  • joint, muscle, and back pain
  • headache
  • constipation
  • mouth sores
  • respiratory tract infections
  • changes in kidney function blood test
  • changes in the way food tastes
  • loss of appetite
  • low number of platelets
  • indigestion or heartburn

These are not all the possible side effects of LYNPARZA. Call your healthcare provider for medical advice about side effects.

You may report side effects related to AstraZeneca products by clicking here. If you prefer to report these to the FDA, either visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

Please click here for complete Prescribing Information, including Patient Information (Medication Guide).

WHAT IS LYNPARZA?

LYNPARZA is a prescription medicine used to treat adults who have:

  • a certain type of abnormal inherited BRCA gene, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to other parts of the body (metastatic). You should have received chemotherapy medicines, either before or after your cancer has spread. If you have hormone receptor (HR)-positive disease, you should have been treated with hormonal therapy. Your healthcare provider will perform a test to make sure that LYNPARZA is right for you

It is not known if LYNPARZA is safe and effective in children.

IMPORTANT SAFETY INFORMATION

LYNPARZA may cause serious side effects, including: Bone marrow problems called Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML). Some people who have ovarian cancer or breast cancer and who have received previous treatment with chemotherapy, radiotherapy, or certain other medicines for their cancer have developed MDS or AML during treatment with LYNPARZA. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with LYNPARZA.

Symptoms of low blood cell counts are common during treatment with LYNPARZA, but can be a sign of serious bone marrow problems, including MDS or AML. Symptoms may include weakness, weight loss, fever, frequent infections, blood in urine or stool, shortness of breath, feeling very tired, bruising or bleeding more easily.

    Your healthcare provider will do blood tests to check your blood cell counts:
  • before treatment with LYNPARZA
  • every month during treatment with LYNPARZA
  • weekly if you have low blood cell counts that last a long time. Your healthcare provider may stop treatment with LYNPARZA until your blood cell counts improve

Lung problems (pneumonitis). Tell your healthcare provider if you have any new or worsening symptoms of lung problems, including shortness of breath, fever, cough, or wheezing. Your healthcare provider may do a chest x-ray if you have any of these symptoms. Your healthcare provider may temporarily or completely stop treatment if you develop pneumonitis. Pneumonitis may lead to death.

    Before taking LYNPARZA, tell your healthcare provider about all of your medical conditions, including if you:
  • have lung or breathing problems
  • have kidney problems
  • are pregnant, become pregnant, or plan to become pregnant. LYNPARZA can harm your unborn baby and may cause loss of pregnancy (miscarriage)
    • If you are able to become pregnant, your healthcare provider may do a pregnancy test before you start treatment with LYNPARZA
    • Females who are able to become pregnant should use effective birth control (contraception) during treatment with LYNPARZA and for 6 months after the last dose of LYNPARZA. Talk to your healthcare provider about birth control methods that may be right for you. Tell your healthcare provider right away if you become pregnant or think you might be pregnant following treatment with LYNPARZA
    • Males with female partners who are pregnant or who are able to become pregnant should use effective birth control (contraception) during treatment with LYNPARZA and for 3 months after the last dose of LYNPARZA
    • Do not donate sperm during treatment with LYNPARZA and for 3 months after your final dose
  • are breastfeeding or plan to breastfeed. It is not known if LYNPARZA passes into your breast milk. Do not breastfeed during treatment with LYNPARZA and for 1 month after receiving the last dose of LYNPARZA. Talk to your healthcare provider about the best way to feed your baby during this time

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking LYNPARZA and certain other medicines may affect how LYNPARZA works and may cause side effects.

    How should I take LYNPARZA?
  • Take LYNPARZA tablets exactly as your healthcare provider tells you
  • Do not change your dose or stop taking LYNPARZA unless your healthcare provider tells you to. Your healthcare provider may temporarily stop treatment with LYNPARZA or change your dose of LYNPARZA if you experience side effects
  • Your healthcare provider will decide how long you stay on treatment
  • Do not take more than 4 LYNPARZA tablets in 1 day. If you have any questions about LYNPARZA, talk to your healthcare provider or pharmacist
  • Take LYNPARZA by mouth 2 times a day
  • Each dose should be taken about 12 hours apart
  • Swallow LYNPARZA tablets whole. Do not chew, crush, dissolve, or divide the tablets
  • Take LYNPARZA with or without food
  • If you miss a dose of LYNPARZA, take your next dose at your usual scheduled time. Do not take an extra dose to make up for a missed dose
  • If you take too much LYNPARZA, call your healthcare provider or go to the nearest hospital emergency room right away

What should I avoid while taking LYNPARZA?Avoid grapefruit, grapefruit juice, Seville oranges, and Seville orange juice during treatment with LYNPARZA since they may increase the level of LYNPARZA in your blood.

    LYNPARZA may cause serious side effects (see above). The most common side effects of LYNPARZA are:
  • nausea or vomiting. Tell your healthcare provider if you get nausea or vomiting. Your healthcare provider may prescribe medicines to treat these symptoms
  • low number of red or white blood cells
  • stomach-area (abdominal) pain
  • dizziness
  • tiredness or weakness
  • sore throat or runny nose
  • diarrhea
  • joint, muscle, and back pain
  • headache
  • constipation
  • mouth sores
  • respiratory tract infections
  • changes in kidney function blood test
  • changes in the way food tastes
  • loss of appetite
  • low number of platelets
  • indigestion or heartburn

These are not all the possible side effects of LYNPARZA. Call your healthcare provider for medical advice about side effects.

You may report side effects related to AstraZeneca products by clicking here. If you prefer to report these to the FDA, either visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

Please click here for complete Prescribing Information, including Patient Information (Medication Guide).